ReviewBest practice & research. Clinical gastroenterology2010
Primary biliary cirrhosis.
Review in Best practice & research. Clinical gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Extrahepatic autoimmune conditions associated with primary biliary cirrhosis.Clinical reviews in allergy & immunology · 2015Pooled it
- Cholestatic and autoimmune liver diseases, bile duct injury, oxidative stress, and therapeutic strategies.Frontiers in physiology · 2026Review
- Late-onset paradoxical response 11 years after treatment of tuberculous hepatic abscesses in an HIV-negative patient: a case report and literature review.Clinical journal of gastroenterology · 2025Review
- Biliary fibrosis is an important but neglected pathological feature in hepatobiliary disorders: from molecular mechanisms to clinical implications.Medical review (2021) · 2024Review
- "MRI periportal halo sign" in primary biliary cirrhosis.Abdominal radiology (New York) · 2023Article
- Research experimental design for the construction and identification of the pGEX-BCKD-E4A recombinant point-mutant plasmid.PloS one · 2023Article
- Article
- Can simple Non-Invasive Fibrosis Models Determine Prognostic Indicators (Fibrosis and Treatment Response) of Primary Biliary Cholangitis?Sisli Etfal Hastanesi tip bulteni · 2021Article
- Identifying side effects of commonly used drugs in the treatment of Covid 19.Scientific reports · 2020Review
- Liver assessment using Gd-EOB-DTPA-enhanced magnetic resonance imaging in primary biliary cholangitis patients.Japanese journal of radiology · 2019Article
- External validation of the United Kingdom-primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid.Hepatology communications · 2018Article
- Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.Seminars in liver disease · 2017Article
- The Burnout Conundrum: Nature Versus Nurture?Journal of graduate medical education · 2016Article
- Extrahepatic malignancies in primary biliary cirrhosis: a comparative study at two European centers.Clinical reviews in allergy & immunology · 2015Article
- Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy.World journal of hepatology · 2015Review
- The value of MRI in the diagnosis of primary biliary cirrhosis and assessment of liver fibrosis.PloS one · 2015Article
- Differential binding of pyruvate dehydrogenase complex-E2 epitopes by DRB1*08:01 and DRB1*11:01 Is predicted by their structural motifs and correlates with disease risk.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- Integrative role of MRI in the evaluation of primary biliary cirrhosis.European radiology · 2012Article
- Primary biliary cirrhosis in a rheumatoid arthritis patient treated with rituximab, a case-based review.Clinical rheumatology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Primary biliary cirrhosis (PBC) is an idiopathic chronic autoimmune liver disease that primarily affects women. It is believed that the aetiology for PBC is a combination between environmental triggers in genetically vulnerable persons. The diagnosis for PBC is made when two of the three criteria are fulfilled and they are: (1) biochemical evidence of cholestatic liver disease for at least 6 month's duration; (2) anti-mitochondrial antibody (AMA) positivity; and (3) histologic features of PBC on liver biopsy. Ursodeoxycholic acid (UDCA) is the only FDA-approved medical treatment for PBC and should be administered at a recommended dose of 13-15 mg/kg/day. Unfortunately despite adequate dosing of UDCA, approximately one-third of patients does not respond adequately and may require liver transplantation. Future studies are necessary to elucidate the role of environmental exposures and overall genetic impact not only in the development of PBC, but on disease progression and variable clinical response to therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.